Raise closed, search for fresh raises on Seedstage

Mountain View, CA

Scaling AI-powered drug discovery solutions to optimize healthcare innovation.

• Revolutionary AI platforms: SentinusAI®, CarbonAI®, and CellulaAI™ reduce costs and timelines for drug discovery.
• Market opportunity: Positioned in a $30 billion biotech AI service market with significant growth potential.
• Experienced leadership: Decades of expertise in AI and pharmaceutical R&D drive innovation.
• Proven traction: Nearly $1 million in revenue since inception, addressing critical inefficiencies in drug development.
• Strategic growth: Expanding partnerships and service offerings to meet global demand for scalable healthcare solutions.

Ainnocence is transforming the landscape of drug discovery with its advanced AI-driven platforms—SentinusAI®, CarbonAI®, and CellulaAI™—designed to optimize research and development processes in biotechnology and pharmaceuticals. These cutting-edge tools aim to address longstanding inefficiencies in drug discovery, offering solutions that can reduce costs by up to 80% and significantly shorten development timelines. By virtually screening billions of molecules and refining therapeutic designs, Ainnocence empowers clients to achieve higher success rates in developing life-saving therapies. The company operates with a dual business model, combining service-based solutions and co-development opportunities, to generate sustainable revenue and drive impactful innovation in the life sciences market.

With a global pharmaceutical market projected to exceed $214 billion by 2032, Ainnocence focuses on a $30 billion niche within biotech AI services. Backed by nearly $1 million in revenue since its inception and led by a team with decades of experience in AI, computational biology, and pharmaceutical R&D, Ainnocence is well-positioned to meet the growing demand for ethical, cost-effective, and scalable drug discovery technologies. Funds raised will accelerate the company’s expansion, support collaborations with leading biotech organizations, and enhance its ability to tackle critical healthcare challenges through innovative, AI-driven solutions.

Company Info

Ainnocence utilizes AI-driven platforms to optimize and accelerate drug discovery, reducing costs and development timelines.

Ainnocence is a pioneering biotech company leveraging AI-driven platforms—SentinusAI®, CarbonAI®, and CellulaAI™—to revolutionize drug discovery. These platforms are designed to optimize the drug discovery process, reducing R&D costs by up to 80% and shortening development timelines from years to weeks. Ainnocence’s advanced AI systems address critical inefficiencies in traditional drug discovery, offering innovative solutions to biotech and pharmaceutical sectors. By virtually screening billions of molecules and optimizing design processes, Ainnocence enables higher therapeutic success rates, making drug discovery faster, more affordable, and scalable.

With nearly $1M in revenue since its inception, Ainnocence is positioned to disrupt the life sciences market by providing ethical, cost-effective drug discovery solutions. The company targets the growing $30 billion biotech AI service market and aims to expand its service offerings to meet the increasing demand for innovative and efficient drug development technologies. Backed by a team with extensive expertise in AI, computational biology, and pharmaceutical R&D, Ainnocence is on track to become a key player in the global biotech and pharmaceutical industries.